Slingshot members are tracking this event:

Portola (PTLA) FDA Advisory Committee Meeting in Q2 2017 for Betrixaban in the Prevention of VTE in Acute Medically Ill Patients

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Management Comment FDA Informs Portola Pharmaceuticals at Mid-Cycle Review for Betrixaban That It Has Not Identified Issues that Require an Advisory Committee Meeting
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 08, 2017
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Fda, Advisory Committee Meeting, Betrixaban, Vte, Acute Medically Ill Patients